The atorvastatin during ischemic stroke study: A pilot randomized controlled trial

Clinical Neuropharmacology

Volumn 34, Issue 4, 2011, Pages 141-147

  Muscari, Antonio ^a   Puddu, Giovanni M ^a   Santoro, Nadia ^a   Serafini, Claudia ^a   Cenni, Andrea ^a   Rossi, Valentina ^a   Zoli, Marco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atorvastatin; ischemic stroke; neuroprotection; pilot study; randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SIMVASTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTIOXIDANTS; BRAIN INFARCTION; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLES; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051509487     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182206c2f     Document Type: Article

References (31)

1. Laloux P, Thijs V, Peeters A, et al. Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. Is time the only barrier? Acta NeurolBelg 2007;107:103-107. (Pubitemid 351447421)
2. Kleindorfer D, Lindsell CJ, Brass L, et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928. (Pubitemid 351619542)
3. Shuaib A, Hussain MS. The past and future of neuroprotection in cerebral ischaemic stroke. Eur Neurol 2008;59:4-14. (Pubitemid 350277253)
4. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885. (Pubitemid 28350583)
5. Li J, Li JJ, He JG, et al. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc Ther 2010;28:8-14.
6. Teupser D, Bruegel M, Stein O, et al. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem BiophysRes Commun 2001;289:838-844. (Pubitemid 34060080)
7. KruithofEK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008;100:969-975.
8. Haslinger B, Kleemann R, Toet KH, et al. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int 2003;63:2065-2074. (Pubitemid 36605817)
9. Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003;23:322-327. (Pubitemid 36231947)
10. Hayashi A, Suzuki M, Ogawa Y, et al. Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat Pharm Pharmacol 2004;56:893-898. (Pubitemid 38885983)
11. Berger C, Xia F, Maurer MH, et al. Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev 2008;58:48-56. (Pubitemid 351852927)
12. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. NEngl JMed 2006;355:549-559.
13. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study. Neurology 2008;70:2364-2370.
14. Greisenegger S, Müllner M, Tentschert S, et al. Effect ofpretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004;221:5-10. (Pubitemid 38721284)
15. Shook SJ, Gupta R, Vora NA, et al. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. Neuroimaging 2006;16:341-346. (Pubitemid 44521385)
16. Ovbiagele B, Saver JL, Starkman S, et al. Statin enhancement of collateralization in acute stroke. Neurology 2007;68:2129-2131. (Pubitemid 46912132)
17. Mart́?-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-1121.
18. Goldstein LB, Amarenco P, Zivin J, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009;40:3526-3531.
19. Mart́?nez-Sánchez P, Rivera-Ordóñez C, Fuentes B, et al The beneficial effect ofstatins treatment by stroke subtype. Eur J Neurol 2009; 16:127-133.
20. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-910. (Pubitemid 47329591)
21. Moonis M, Kane K, Schwiderski U, et al. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005;36:1298-1300. (Pubitemid 40798758)
22. Kurzepa J, Bielewicz J, Bartosik-Psujek H, et al. Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke. PharmacolRep 2008;60:1014-1018.
23. Montaner J, Chacón P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90. (Pubitemid 350265291)
24. Lampl Y, Lorberboym M, Gilad R, et al. Early outcome ofacute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin. Clin Neuropharmacol 2010;33:129-134.
25. Gresser U, GathofBS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis ofrandomized controlled endpoint studies. Eur J MedRes 2004;9:1-17.
26. Lansberg MG, O'Brien MW, Tong DC, et al. Evolution ofcerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. Arch Neurol 2001;58:613-617. (Pubitemid 32295713)
27. Tourdias T, Renou P, Sibon I, et al. Final cerebral infarct volume is predictable by MR imaging at 1 week. AJNR Am JNeuroradiol 2011;32:352-358.
28. The National Institute ofNeurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. NEngl JMed 1995;333:1581-1587.
29. Saqqur M, Uchino K, Demchuk AM, et al. CLOTBUST Investigators. Site ofarterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38:948-954. (Pubitemid 46568457)
30. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-751. (Pubitemid 36622511)
31. Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilottrial. Lancet Neurol 2007;6:961-969. (Pubitemid 47562312)